Amalgamated Financial’s PMV Pharmaceuticals PMVP Stock Holding History

Amalgamated Financial’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$89K	Buy	+4,271	New	+$75.3K	﹤0.01%	2192

Other funds holding PMVP

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Amalgamated Financial's PMVP Position: Q1 2022 in Review

Amalgamated Financial opened a new position in PMV Pharmaceuticals (PMVP) in Q1 2022: 4,271 shares worth $89K. The stake represents ﹤0.01% of the portfolio and ranks #2192 among its holdings.

99 funds tracked by Wall St. Rank hold PMVP as of Q1 2022.

Amalgamated Financial held 4,271 shares of PMV Pharmaceuticals worth $89K as of Q1 2022.
PMV Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
PMV Pharmaceuticals made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2192 holding.
99 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.